223Ra-二氯化物治疗去势抵抗性转移性前列腺癌:临床实践中的疗效改善与生存预测因素
该回顾性队列研究纳入2年内接受223Ra-二氯化物治疗的57例去势抵抗性转移性前列腺癌患者,中位随访298天。第二年的转诊模式改善,骨病范围(EOBD)1级患者比例更高,且总生存与基线总碱性磷酸酶(tALP)、tALP应答及无淋巴结病变相关。作者认为多学科转诊路径和用药经验积累改善了结局,tALP动态可用于监测应答和预测总生存。
要点
- 第二年EOBD1患者比例高于第一年(29% vs 4%),且第二年症状性骨骼相关事件率更低、完成六周期比例更高。
- EOBD4患者与其他所有组、EOBD1与EOBD3患者之间的总生存存在显著差异(p < 0.05)。
- 基线tALP正常者总生存长于基线tALP升高者(p = 0.01),tALP应答者总生存长于无应答者(p < 0.05)。
核心结论
- 多学科协作转诊路径联合223Ra-二氯化物用药经验增加,带来了结局改善。
- 在基线tALP升高的患者中,tALP动态可能有助于监测应答和预测总生存。
- 影像学和预后标志物可能有助于个体化223Ra-二氯化物治疗及规划再治疗,但需进一步研究。
研究设计与样本
- 回顾性评估并前瞻性随访57例符合223Ra-二氯化物治疗条件的患者,时间跨度为2014年3月至2016年3月共2年,中位随访298天。
- 223Ra-二氯化物以4周间隔给药,最多六次注射。
- 比较第一年和第二年转诊患者的骨病范围(EOBD)分类及总生存,并评估EOBD分类、基线tALP、tALP应答、任何治疗周期中tALP较基线最大百分比下降(ALPmax,限基线tALP升高患者)及淋巴结病变作为总生存预测因素。
主要发现
- 第二年EOBD1患者比例高于第一年(29% vs 4%),第二年症状性骨骼相关事件率更低、完成六周期比例更高、总生存更长但无统计学显著差异(p = 0.55)。
- EOBD4患者与其他所有组之间、EOBD1与EOBD3患者之间的总生存存在显著差异(p < 0.05)。
- 基线tALP正常者总生存长于基线tALP升高者(p = 0.01)。
- tALP应答者总生存长于无应答者(p < 0.05)。
- 无淋巴结病变者总生存长于有淋巴结病变者(p = 0.29),总生存与ALPmax相关(r2 = 0.24)。
临床怎么用
- 原文结论指出多学科协作转诊路径联合用药经验增加带来了结局改善,但未据此给出具体临床推荐。
- 作者认为在基线tALP升高的患者中,tALP动态可能有助于监测应答和预测总生存。
- 作者认为影像学和预后标志物可能有助于个体化223Ra-二氯化物治疗及规划再治疗。
局限性
- 原文结论指出需进一步研究(further studies are required)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We first assessed whether the pattern of referrals to a nuclear medicine clinic improved as experience with 223Ra-dichloride increased, and whether referral patterns affected patient outcomes, and second assessed the value of bone scintigraphy, total alkaline phosphatase (tALP) and lymphadenopathy as prognostic factors in patients receiving 223Ra-dichloride. METHODS: A total of 57 patients eligible to receive 223Ra-dichloride over a 2-year period (March 2014 to March 2016) were retrospectively assessed and prospectively followed (median follow up 298 days). 223Ra-Dichloride was administered at 4-week intervals for a maximum of six injections. The numbers of patients in years 1 and 2 referred in relation to extent of bone disease (EOBD) category and overall survival (OS) were determined. The prognostic factors EOBD category, baseline tALP (tALPBL), tALP response, greatest percentage reduction in tALP from baseline in any treatment cycle (ALPmax; among patients with elevated ALPBL), and the presence of lymphadenopathy were assessed as predictors of OS. RESULTS: The proportion of patients with EOBD1 was higher in year 2 than in year 1 (29% and 4%, respectively), and in year 2 there was a lower rate of symptomatic skeleton-related events, a higher proportion of patients completing six cycles, and longer (albeit nonsignificant) OS (p = 0.55). There were significant differences in OS between EOBD4 patients and those in all other groups and between EOBD1 and EOBD3 patients (p < 0.05). OS was longer in patients with normal tALPBL than in those with elevated tALPBL (p = 0.01), in ALP responders than in nonresponders (p < 0.05), and in patients without lymphadenopathy than in those with lymphadenopathy (p = 0.29). OS was correlated with ALPmax (r2 = 0.24). CONCLUSION: A collaborative multidisciplinary referrals pathway, together with increased experience with 223Ra-dichloride, led to improved outcomes. In patients with elevated tALPBL, tALP dynamics may be useful for monitoring response and predicting OS. Imaging and prognostic markers may therefore be of value for individualizing 223Ra-dichloride treatment and planning retreatment; however, further studies are required.
引用
- Dizdarevic S, Jessop M, Begley P, et al. 223Ra-Dichloride in castration-resistant metastatic prostate cancer: improving outcomes and identifying predictors of survival in clinical practice. Eur J Nucl Med Mol Imaging. 2018. PMID: 29998419. doi:10.1007/s00259-018-4083-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。